120 related articles for article (PubMed ID: 22414039)
41. In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients.
Carrió J; Riera C; Gállego M; Ribera E; Portús M
J Antimicrob Chemother; 2001 Jan; 47(1):120-1. PubMed ID: 11152446
[No Abstract] [Full Text] [Related]
42. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
43. Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.
Bianciardi P; Brovida C; Valente M; Aresu L; Cavicchioli L; Vischer C; Giroud L; Castagnaro M
Toxicol Pathol; 2009 Oct; 37(6):770-5. PubMed ID: 19690151
[TBL] [Abstract][Full Text] [Related]
44. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
Cascio A; Gradoni L; Scarlata F; Gramiccia M; Giordano S; Russo R; Scalone A; Camma C; Titone L
Am J Trop Med Hyg; 1997 Jul; 57(1):75-8. PubMed ID: 9242323
[TBL] [Abstract][Full Text] [Related]
45. [A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
Oliveira MC; Amorim RF; Freitas Rde A; Costa Ade L
Rev Soc Bras Med Trop; 2005; 38(3):258-60. PubMed ID: 15895180
[TBL] [Abstract][Full Text] [Related]
46. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
48. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Manna L; Vitale F; Reale S; Picillo E; Neglia G; Vescio F; Gravino AE
Vet J; 2009 Dec; 182(3):441-5. PubMed ID: 18818112
[TBL] [Abstract][Full Text] [Related]
49. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
[TBL] [Abstract][Full Text] [Related]
50. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
51. Effectiveness of intralesional meglumine antimoniate in the treatment of mucosal leishmaniasis of the Old World.
Zaraa I; Karoui S; Osman AB
J Dermatol; 2012 Feb; 39(2):201-3. PubMed ID: 21950659
[No Abstract] [Full Text] [Related]
52. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
53. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
54. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
55. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
56. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
[TBL] [Abstract][Full Text] [Related]
58. Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.
Juzlova K; Votrubova J; Kacerovska D; Lukas M; Bortlik M; Rohacova H; Nohynkova E; Vojackova N; Fialova J; Hercogova J
Dermatol Ther; 2014; 27(3):131-4. PubMed ID: 24903470
[TBL] [Abstract][Full Text] [Related]
59. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
60. Natural Resistance of
Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
